From chemotherapy to biotechnology: the transformation of the cancer research pipeline at Hoffmann-La Roche

Abstract This paper analyses the history of the research and development pipeline for anticancer drugs at the pharmaceutical company Hoffmann-La Roche from the 1950s to the early 2000s. I argue that the history of Roche’s oncology drugs exemplifies a major transformation in the pharmaceutical industry, from a chemistry-driven innovation model, relying predominantly on research in company-owned laboratories, developing chemotherapies for infectious diseases, towards one that is organised around molecular biology and collaborations with biotech companies and that appears to be targeting primarily cancer, employing relatively expensive biological compounds. While the shift to molecular biology and collaborations with biotech companies has received considerable attention from scholars of innovation, the majority of this literature deals with the early stages of this development. My case studies allow me to look at the impact of research on oncogenes and monoclonal antibody technology, which has been less extensively studied. I will look to programmatic publications by Roche’s Head of Research in the late 1980s and 1990s, Jürgen Drews, to contextualise this transformation. The case studies the paper discusses in detail are the histories of the anticancer drugs 5-Fluoro-Uracil (5-FU), classed as an antimetabolite and approved by the FDA in 1962, procarbazine (marketed as Natulan), another traditional chemotherapy drug that received FDA approval in 1969, and the monoclonal antibody compounds rituxan (marketed as Rituxan or Mabthera and approved by the FDA in 1997), trastuzumab (Herceptin, FDA approval in 1998), and bevacizumab (Avastin, approved by the FDA in 2004). While the developments mapped in this paper appear to illustrate a divergence of approaches in the development of antimicrobial and cancer drugs, they can also be read as a shift towards a new interpretation of an old paradigm: monoclonal antibodies as the ultimate magic bullets, that can also be employed to treat other conditions, including those caused by microbes.

Authors

Institutions

Publication Details

Journal
Humanities and Social Sciences Communications
Published
2025-04-26
DOI
https://doi.org/10.1057/s41599-025-04812-0
Citations
2
Primary Topic
Historical Medical Research and Treatments
Type
article
Field-Weighted Citation Impact
2.72
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

From chemotherapy to biotechnology: the transformation of the cancer research pipeline at Hoffmann-La Roche

Carsten Timmermann
2 citations
Humanities and Social Sciences Communications
Historical Medical Research and Treatments
2.72
article

From chemotherapy to biotechnology: the transformation of the cancer research pipeline at Hoffmann-La Roche

Carsten Timmermann
article en
2 citations

Abstract

Abstract This paper analyses the history of the research and development pipeline for anticancer drugs at the pharmaceutical company Hoffmann-La Roche from the 1950s to the early 2000s. I argue that the history of Roche’s oncology drugs exemplifies a major transformation in the pharmaceutical industry, from a chemistry-driven innovation model, relying predominantly on research in company-owned laboratories, developing chemotherapies for infectious diseases, towards one that is organised around molecular biology and collaborations with biotech companies and that appears to be targeting primarily cancer, employing relatively expensive biological compounds. While the shift to molecular biology and collaborations with biotech companies has received considerable attention from scholars of innovation, the majority of this literature deals with the early stages of this development. My case studies allow me to look at the impact of research on oncogenes and monoclonal antibody technology, which has been less extensively studied. I will look to programmatic publications by Roche’s Head of Research in the late 1980s and 1990s, Jürgen Drews, to contextualise this transformation. The case studies the paper discusses in detail are the histories of the anticancer drugs 5-Fluoro-Uracil (5-FU), classed as an antimetabolite and approved by the FDA in 1962, procarbazine (marketed as Natulan), another traditional chemotherapy drug that received FDA approval in 1969, and the monoclonal antibody compounds rituxan (marketed as Rituxan or Mabthera and approved by the FDA in 1997), trastuzumab (Herceptin, FDA approval in 1998), and bevacizumab (Avastin, approved by the FDA in 2004). While the developments mapped in this paper appear to illustrate a divergence of approaches in the development of antimicrobial and cancer drugs, they can also be read as a shift towards a new interpretation of an old paradigm: monoclonal antibodies as the ultimate magic bullets, that can also be employed to treat other conditions, including those caused by microbes.

Humanities and Social Sciences CommunicationsVol. 12(1)
University of Manchester (GB)
Openalex Percentile: Top 11%
Historical Medical Research and Treatments
2.72
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

From chemotherapy to biotechnology: the transformation of the cancer research pipeline at Hoffmann-La Roche — Carsten Timmermann · Humanities and Social Sciences Communications (2025) | TGRS Research Map | TGRS